Search Results - "Alberti, Dona"

Phase I Trial of 2-Methoxyestradiol NanoCrystal Dispersion in Advanced Solid Malignancies by TEVAARWERK, Amyej, HOLEN, Kyle D, ALBERTI, Dona B, SIDOR, Carolyn, ARNOTT, Jamie, QUON, Check, WILDING, George, LIU, Glenn

“…Purpose: 2-Methoxyestradiol (2ME2; Panzem) is an endogenous, estradiol-17β metabolite that at pharmacologic doses exerts antimitotic and antiangiogenic…”
Get full text

Safety and Immunological Efficacy of a DNA Vaccine Encoding Prostatic Acid Phosphatase in Patients With Stage D0 Prostate Cancer by MCNEEL, Douglas G, DUNPHY, Edward J, LIU, Glenn, EICKHOFF, Jens C, WILDING, George, DAVIES, James G, FRYE, Thomas P, JOHNSON, Laura E, STAAB, Mary Jane, HORVATH, Dorothea L, STRAUS, Jane, ALBERTI, Dona, MARNOCHA, Rebecca

“…Prostatic acid phosphatase (PAP) is a prostate tumor antigen. We have previously demonstrated that a DNA vaccine encoding PAP can elicit antigen-specific CD8+…”
Get full text

A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer by Schelman, William R., Mohammed, Tabraiz A., Traynor, Anne M., Kolesar, Jill M., Marnocha, Rebecca M., Eickhoff, Jens, Keppen, Michael, Alberti, Dona B., Wilding, George, Takebe, Naoko, Liu, Glenn

“…Summary Background . A phase I, dose-escalation study of AT-101 with cisplatin and etoposide was conducted to determine the maximum tolerated dose…”
Get full text

A Phase I Trial of Perifosine (NSC 639966) on a Loading Dose/Maintenance Dose Schedule in Patients with Advanced Cancer by VAN UMMERSEN, Lynn, BINGER, Kim, VOLKMAN, Jennifer, MARNOCHA, Rebecca, TUTSCH, Kendra, KOLESAR, Jill, ARZOOMANIAN, Rhoda, ALBERTI, Dona, WILDING, George

“…Perifosine (NSC 639966) is a synthetic, substituted heterocyclic alkylphosphocholine that acts primarily at the cell membrane targeting signal transduction…”
Get full text

Phase I Trial of a Monoclonal Antibody Specific for αvβ3 Integrin (MEDI-522) in Patients with Advanced Malignancies, Including an Assessment of Effect on Tumor Perfusion by MCNEEL, Douglas G, EICKHOFF, Jens, JIANLIANG ZHANG, HAMMERSHAIMB, Luz, ZWIEBEL, James A, WILDING, George, LEE, Fred T, KING, David M, ALBERTI, Dona, THOMAS, James P, FRIEDL, Andreas, KOLESAR, Jill, MARNOCHA, Rebecca, VOLKMAN, Jennifer

“…At present, a variety of agents targeting tumor angiogenesis are under clinical investigation as new therapies for patients with cancer. Overexpression of the…”
Get full text

Phase I Pharmacokinetic and Pharmacodynamic Study of Recombinant Human Endostatin in Patients With Advanced Solid Tumors by THOMAS, James P, ARZOOMANIAN, Rhoda Z, FOGLER, William, SCHILLER, Joan H, WILDING, George, ALBERTI, Dona, MARNOCHA, Rebecca, LEE, Fred, FRIEDL, Andreas, TUTSCH, Kendra, DRESEN, Amy, GEIGER, Peter, PLUDA, James

“…Endostatin is the first endogenous angiogenesis inhibitor to enter clinical trials. Laboratory investigations with endostatin have indicated broad antitumor…”
Get full text

Randomized, Double-Blinded Phase II Evaluation of Docetaxel with or without Doxercalciferol in Patients with Metastatic, Androgen-Independent Prostate Cancer by Attia, Steven, Eickhoff, Jens, Wilding, George, McNeel, Douglas, Blank, Jules, Ahuja, Harish, Jumonville, Alcee, Eastman, Michael, Shevrin, Daniel, Glode, Michael, Alberti, Dona, Staab, Mary Jane, Horvath, Dottie, Straus, Jane, Marnocha, Rebecca, Liu, Glenn

“…Purpose: Docetaxel is standard of care for androgen-independent prostate cancer (AIPC). Doxercalciferol (1α-hydroxyvitamin D2) had modest activity in phase…”
Get full text

A Phase I and Pharmacologic Trial of Two Schedules of the Proteasome Inhibitor, PS-341 (Bortezomib, Velcade), in Patients with Advanced Cancer by DY, Grace K, THOMAS, James P, HANSON, Lorelei J, MARNOCHA, Rebecca, TUTSCH, Kendra, KAUFMANN, Scott H, ADJEI, Alex A, WILDING, George, BRUZEK, Laura, MANDREKAR, Sumithra, ERLICHMAN, Charles, ALBERTI, Dona, BINGER, Kim, PITOT, Henry C, ALBERTS, Steven R

“…Purpose: To define the toxicities, pharmacodynamics, and clinical activity of the proteasome inhibitor, PS-341 (bortezomib), in patients with advanced…”
Get full text

maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors by Choi, Brian S, Alberti, Dona B, Schelman, William R, Kolesar, Jill M, Thomas, James P, Marnocha, Rebecca, Eickhoff, Jens C, Ivy, S. Percy, Wilding, George, Holen, Kyle D

“…Purpose 3-AP is a ribonucleotide reductase inhibitor and has been postulated to act synergistically with other chemotherapeutic agents. This study was…”
Get full text

Phase II Study of 1α-Hydroxyvitamin D2 in the Treatment of Advanced Androgen-independent Prostate Cancer by LIU, Glenn, WILDING, George, STAAB, Mary Jane, HORVATH, Dorthea, MILLER, Kelly, DRESEN, Amy, ALBERTI, Dona, ARZOOMANIAN, Rhoda, CHAPPELL, Rick, BAILEY, Howard H

“…Purpose: In this single institution Phase II trial, we evaluated the efficacy of the vitamin D analogue, 1α-OH-D 2 , in patients with advanced…”
Get full text

Electron paramagnetic resonance study of peripheral blood mononuclear cells from patients with refractory solid tumors treated with Triapine by Kolesar, Jill M., Schelman, William R., Geiger, Peter G., Holen, Kyle D., Traynor, Anne M., Alberti, Dona B., Thomas, James P., Chitambar, Christopher R., Wilding, George, Antholine, William E.

“…The metal chelator Triapine®, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, is a potent inhibitor of ribonucleotide reductase. EPR spectra consistent…”
Get full text

Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol by THOMAS, James P, TUTSCH, Kendra D, DRESEN, Amy, WILDING, George, CLEARY, James F, BAILEY, Howard H, ARZOOMANIAN, Rhoda, ALBERTI, Dona, SIMON, Kris, FEIERABEND, Chris, BINGER, Kimberly, MARNOCHA, Rebecca

“…Flavopiridol (NSC 649890) is a synthetic flavone possessing significant antitumor activity in preclinical models. Flavopiridol is capable of inducing cell…”
Get full text

Phase I Trial of Weekly Paclitaxel and BMS-214662 in Patients with Advanced Solid Tumors by BAILEY, Howard H, ALBERTI, Dona B, THOMAS, James P, MULKERIN, Daniel L, BINGER, Kimberly A, GOTTARDIS, Marco M, MARTELL, Robert E, WILDING, George

“…Purpose: To assess the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), pharmacodynamics, and antitumor activity of continuous weekly-administered…”
Get full text

A Phase I Pharmacokinetic and Pharmacodynamic Correlative Study of the Antisense Bcl-2 Oligonucleotide G3139, in Combination with Carboplatin and Paclitaxel, in Patients with Advanced Solid Tumors by Liu, Glenn, Kolesar, Jill, McNeel, Douglas G, Leith, Catherine, Schell, Kathy, Eickhoff, Jens, Lee, Fred, Traynor, Anne, Marnocha, Rebecca, Alberti, Dona, Zwiebel, James, Wilding, George

“…Purpose: This phase I trial assessed the safety and tolerability of G3139 when given in combination with carboplatin and paclitaxel chemotherapy. The effect of…”
Get full text

Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors by Kolesar, Jill, Huang, Wei, Eickhoff, Jens, Hahn, Kristine, Alberti, Dona, Attia, Steven, Schelman, William, Holen, Kyle, Traynor, Anne, Ivy, Percy, Wilding, George

“…Purpose The purpose of this study was to evaluate baseline RRM2 protein and gene expression in tumors of patients receiving 3-AP. Methods Tumor blocks from…”
Get full text

Phase I Trial of 1α-Hydroxyvitamin D2 in Patients with Hormone Refractory Prostate Cancer by LIU, Glenn, OETTEL, Kurt, BISHOP, Charles, BHATTACHARYA, Abhik, BAILEY, Howard, WILDING, George, RIPPLE, Gregory, STAAB, Mary Jane, HORVATH, Dorothea, ALBERTI, Dona, ARZOOMANIAN, Rhoda, MARNOCHA, Rebecca, BRUSKEWITZ, Reginald, MAZESS, Richard

“…This Phase I study of 1α-hydroxyvitamin D 2 , an p.o. administered vitamin D analogue, in patients with advanced hormone-refractory prostate cancer was…”
Get full text

Phase I Clinical and Pharmacokinetic Study of Perillyl Alcohol Administered Four Times a Day by RIPPLE, G. H, GOULD, M. N, MARNOCHA, R, WILDING, G, BAILEY, H. H, ARZOOMANIAN, R. Z, ALBERTI, D, FEIERABEND, C, SIMON, K, BINGER, K, TUTSCH, K. D, POMPLUN, M, WAHAMAKI, A

“…We conducted a phase I dose-escalation trial of perillyl alcohol (POH; NSC 641066) given p.o. on a continuous four times a day basis to characterize the…”
Get full text

Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies by Attia, Steven, Morgan-Meadows, Sherry, Holen, Kyle D, Bailey, Howard H, Eickhoff, Jens C, Schelman, William R, Traynor, Anne M, Mulkerin, Daniel L, Campbell, Toby C, McFarland, Thomas A, Huie, Michael S, Cleary, James F, Tevaarwerk, Amye J, Alberti, Dona B, Wilding, George, Liu, Glenn

“…Purpose To define dose limiting toxicities (DLTs) and the maximum tolerated dose (MTD) of capecitabine with fixed-dose rate (FDR) gemcitabine. Methods Eligible…”
Get full text

Cytotoxic evaluation of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in peripheral blood lymphocytes of patients with refractory solid tumors using electron paramagnetic resonance by KOLESAR, JILL M, SACHIDANANDAM, KAMAKSHI, SCHELMAN, WILLIAM R, EICKHOFF, JENS, HOLEN, KYLE D, TRAYNOR, ANNE M, ALBERTI, DONA B, THOMAS, JAMES P, CHITAMBAR, CHRISTOPHER R, WILDING, GEORGE, ANTHOLINE, WILLIAM E

“…3-Aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) is a metal chelator that potently inhibits the enzyme ribonucleotide reductase (RR), which plays a…”
Get full text

Phase I Clinical and Pharmacokinetic Study of NSC 655649, a Rebeccamycin Analogue, Given in Both Single-Dose and Multiple-Dose Formats by MERCHANT, Joseph, TUTSCH, Kendra, WILDING, George, DRESEN, Amy, ARZOOMANIAN, Rhoda, ALBERTI, Dona, FEIERABEND, Chris, BINGER, Kim, MARNOCCHA, Rebecca, THOMAS, James, CLEARY, Jim

“…Purpose: NSC 655649 was given in both single- and multiple-dose formats, to characterize maximum tolerated dose (MTD), toxicity, and pharmacokinetic profile…”
Get full text